IGEA Pharma NV
SIX:IGPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Getinge AB
STO:GETI B
|
SE |
IGEA Pharma NV
Capital Expenditures
IGEA Pharma NV
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IGEA Pharma NV
SIX:IGPH
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
ONWARD Medical NV
XBRU:ONWD
|
Capital Expenditures
-€432k
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
IGEA Pharma NV
Glance View
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
